Oncology PET/MRI shows strengths, but faces hurdles

March 17, 2016

While the use of PET/MRI is feasible across all types of cancer, it may be tough to show its superiority to PET/CT due to the latter modality's proven track record in detecting and evaluating the disease, according to a review in the March issue of The Journal of Nuclear Medicine.

Researchers from the University of California, Los Angeles (UCLA) surveyed the use of PET/MRI across a broad range of cancers using published literature. They found that while PET/MRI is comparable to PET/CT in many cases, it's particularly beneficial for prostate cancer and bone metastases; however, it falls short in lung nodule assessment.

 

Read the full article.